Leading global law firm Herbert Smith Freehills has advised the joint sponsors of the IPO of SinoMab BioScience Limited on the Main Board of the Stock Exchange of Hong Kong.
The IPO raised approximately HK$1.29 billion and quickly follows TOT BIOPHARM's 8 November IPO, on which the firm also advised.
China International Capital Corporation Hong Kong Securities Limited and Orient Capital (Hong Kong) were the joint sponsors of the listing.
"We are very pleased to have acted on the listing of SinoMab in Hong Kong," said partner Jason Sung. "SinoMab is the twelfth biotech issuer listings under the Chapter 18A and we are privileged to have worked on three of them."
SinoMab BioScience Limited is a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases.
The team advising the joint sponsors of SinoMab BioScience Limited was led by partner Jason Sung, assisted by senior associates George Wu and Lawrence Cheng and associates Kris Cheung and Karen Liu. Additional support provided by Singapore partner Siddhartha Sivaramakrishnan and associate Sophia Tan.